Major depressive disorder
DFTXDefinium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.)Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for DT120 (formerly MM120; lysergide D-tartrate) in Major depressive disorder. The expected timing is based on the latest available company guidance and may change.
Emerge (MM120-310) study. 4/15/25- First patient dosed. 5/8/25- 12wk topline data in H2 2026. 11/06/25:- Emerge Ph3 topline now expected Mid-2026. Ascend Ph3 MDD study planned to start Mid-2026. 05/07/26:- Emerge enrollment completed; topline late Q2 2026. Ascend Ph3 MDD first dosing anticipated in Q2 2026. 05/12/26:- Ascend Ph3 MDD first patient dosed. Ascend topline data anticipated in 2027. 06/22/26:- Emerge Ph3 topline positive; met primary and key secondary endpoints. Next Ascend Ph3 MDD topline remains 2027. 08/06/26:- Emerge Phase 3 positive. Ascend enrollment initiated; topline expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.